Literature DB >> 23108309

Epidermal growth factor receptor signaling in hepatocellular carcinoma: inflammatory activation and a new intracellular regulatory mechanism.

Carmen Berasain1, Alexandra Nicou, Oihane Garcia-Irigoyen, M Ujue Latasa, Raquel Urtasun, Maria Elizalde, Fabiana Salis, María J Perugorría, Jesús Prieto, Juan A Recio, Fernando J Corrales, Matías A Avila.   

Abstract

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is a chemoresistant tumor strongly associated with chronic hepatitis. Identification of molecular links connecting inflammation with cell growth/survival, and characterization of pro-tumorigenic intracellular pathways is therefore of therapeutic interest. The epidermal growth factor receptor (EGFR) signaling system stands at a crossroad between inflammatory signals and intracellular pathways associated with hepatocarcinogenesis. We investigated the regulation and activity of different components of the EGFR system, including the EGFR ligand amphiregulin (AR) and its sheddase ADAM17, and the modulation of intracellular EGFR signaling by a novel mechanism involving protein methylation.
METHODS: ADAM17 protein expression was examined in models of liver injury and carcinogenesis. Crosstalk between tumor necrosis factor (TNF)-α, AR and EGFR signaling was evaluated in human HCC cells and mouse hepatocytes. Modulation of EGFR signaling and biological responses by methylation reactions was evaluated in AML12 mouse hepatocytes.
RESULTS: ADAM17 was upregulated in liver injury and hepatocarcinogenesis. TNF-α triggered AR shedding and EGFR transactivation in HCC cells. AR was necessary for TNF-α activation of ERK1/2 and Akt signaling in hepatocytes. Inhibition of methylation reactions increased the ERK1/2 signal amplitude triggered by AR/EGFR and reduced DNA synthesis in AML12 cells.
CONCLUSIONS: Increased ADAM17 in pre-neoplastic liver injury further supports its implication in hepatocarcinogenesis. AR release and EGFR transactivation by TNF-α constitutes a novel link between inflammatory signals and pro-tumorigenic mechanisms in liver cells. Finally, the identification of a new mechanism controlling growth factor signaling, and biological responses, involving methylation reactions within the RAS/RAF/MEK/ERK pathway, exposes a new target for antineoplastic intervention.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23108309     DOI: 10.1159/000341705

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  15 in total

1.  High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation.

Authors:  Lidan Wu; Allison M Claas; Aniruddh Sarkar; Douglas A Lauffenburger; Jongyoon Han
Journal:  Integr Biol (Camb)       Date:  2015-04-02       Impact factor: 2.192

2.  Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma.

Authors:  Scott M Thompson; Danielle E Jondal; Kim A Butters; Bruce E Knudsen; Jill L Anderson; Matthew P Stokes; Xiaoying Jia; Joseph P Grande; Lewis R Roberts; Matthew R Callstrom; David A Woodrum
Journal:  Int J Hyperthermia       Date:  2017-11-06       Impact factor: 3.914

3.  Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

Authors:  Wenjia Wang; Xiao-Pin Ma; Zhuqing Shi; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexi Ge Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Jielin Sun; S Lilly Zheng; Long Yu; Jianfeng Xu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  ADAM17 substrate release in proximal tubule drives kidney fibrosis.

Authors:  Eirini Kefaloyianni; Muthu Lakshmi Muthu; Jakob Kaeppler; Xiaoming Sun; Venkata Sabbisetti; Athena Chalaris; Stefan Rose-John; Eitan Wong; Irit Sagi; Sushrut S Waikar; Helmut Rennke; Benjamin D Humphreys; Joseph V Bonventre; Andreas Herrlich
Journal:  JCI Insight       Date:  2016-08-18

5.  Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis.

Authors:  Lawrence A Scheving; Xiuqi Zhang; Mary C Stevenson; Michael A Weintraub; Annam Abbasi; Andrea M Clarke; David W Threadgill; William E Russell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-22       Impact factor: 4.052

Review 6.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

7.  The metalloproteinase ADAM17 and the epidermal growth factor receptor (EGFR) signaling drive the inflammatory epithelial response in Sjögren's syndrome.

Authors:  Margherita Sisto; Sabrina Lisi; Massimo D'Amore; Dario Domenico Lofrumento
Journal:  Clin Exp Med       Date:  2014-03-25       Impact factor: 3.984

8.  Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis.

Authors:  Chad McKee; Barbara Sigala; Junpei Soeda; Angelina Mouralidarane; Maelle Morgan; Gianluigi Mazzoccoli; Francesca Rappa; Francesco Cappello; Daniela Cabibi; Valerio Pazienza; Claire Selden; Tania Roskams; Manlio Vinciguerra; Jude A Oben
Journal:  Sci Rep       Date:  2015-03-06       Impact factor: 4.379

9.  Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma.

Authors:  Jian-Zhi Gao; Jing-Li DU; Yong-Ling Wang; Jia Li; Li-Xin Wei; Ming-Zhou Guo
Journal:  Oncol Lett       Date:  2014-11-10       Impact factor: 2.967

Review 10.  EGFR Signaling in Liver Diseases.

Authors:  Karin Komposch; Maria Sibilia
Journal:  Int J Mol Sci       Date:  2015-12-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.